0001376339-26-000031
SEC filingMiMedx reported a 33.1% revenue decline to $59.0M for Q1 2026, resulting in an operating loss of $16.0M. The performance reflects significant headwinds in the Wound Care segment following Medicare reimbursement changes, partially mitigated by continued growth in the Surgical business.
MiMedx experienced a significant revenue contraction in Q1 2026, with total revenue declining 33.1% to $59.0M compared to $88.2M in the prior year period. This decline was primarily driven by lower Wound Care pricing following the Medicare reimbursement changes, as well as unfavorable product mix and higher costs. The pricing pressure in the Wound Care segment represents a structural shift in the company's core market, necessitating a strategic reorientation.
Offsetting the Wound Care challenges, the Surgical business demonstrated continued growth. This increase was driven by continued growth across the AMNIOFIX®, AMNIOEFFECT®, AXIOFILL®, and HELIOGEN™ product lines as adoption expanded across multiple surgical procedures. This divergence between segments highlights the company's ongoing transition toward its Surgical franchise as a key growth driver.
The company reported an operating loss of $16.0M, a significant shift from operating income of $8.3M in Q1 2025. This swing reflects both the revenue decline and continued strategic investments. Research and development costs increased, driven by higher costs associated with the ongoing EPIEFFECT randomized clinical trial, as well as continued investment in the development of future products within the Company's pipeline. These savings were largely offset by increased legal and regulatory expenses, including cost associated with the ongoing litigation with certain competitors and certain former employees.
Net loss for the quarter was $10.9M, or -$0.07 per diluted share, compared to net income of $7.0M, or $0.05 per diluted share, in the prior year. The increase in the effective tax rate was primarily due to the timing of stock-based compensation adjustments, partially offset by limits on the deductibility of executive compensation.
Net cash provided by operating activities was $1.9M, down from $5.3M in the prior year period. The company noted that it generally funds its operating capital requirements through its operating activities and cash reserves. Looking ahead, management expects to use capital to invest in the broadening of our product portfolio, including through potential acquisitions, licensing agreements or other arrangements, the international expansion of our business and certain capital projects. This liquidity position provides flexibility to navigate the Wound Care market transition while continuing to invest in Surgical growth drivers and pipeline development.